Anne C. Melzer

Anne C. Melzer

Auto-generated profile, based on publicly available information

Anne C. Melzer

University of Minnesota Medical School Division of Pulmonary, Allergy, Critical Care and Sleep, Department of Medicine Minneapolis, MN

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
MRMeghan Rebuli
Meghan Rebuli
JRJason J. Rose
Jason J. Rose
ANAlexandra Noel
Alexandra Noel
DCDaniel P. Croft
Daniel P. Croft
NBNeal L. Benowitz
Neal L. Benowitz
TWTheodore J. Witek
Theodore J. Witek
E-cigarette or vaping product use–associated lung injury (EVALI) is a severe pulmonary illness associated with the use of e-cigarettes or vaping products that was officially identified and named in 2019. This American Thoracic Society workshop was convened in 2021 to identify and prioritize research and regulatory needs to adequately respond to the EVALI outbreak and to prevent similar instances of disease associated with e-cigarette or vaping product use. An interdisciplinary group of 26 experts in adult and pediatric clinical care, public health, regulatory oversight, and toxicology were convened for the workshop. Four major topics were examined: 1) the public health and regulatory response to EVALI; 2) EVALI clinical care; 3) mechanisms contributing to EVALI; and 4) needed actions to address the health effects of EVALI. Oral presentations and group discussion were the primary modes used to identify top priorities for addressing EVALI. Initiatives including a national EVALI case registry and biorepository, integrated electronic medical record coding system, U.S. Food and Drug Administration regulation and enforcement of nicotine e-cigarette standards, regulatory authority over nontobacco-derived e-cigarettes, training in evaluating exogenous exposures, prospective clinical studies, standardized clinical follow-up assessments, ability to more readily study effects of cannabinoid e-cigarettes, and research to identify biomarkers of exposure and disease were identified as critical needs. These initiatives will require substantial federal investment as well as changes to regulatory policy. Overall, the workshop identified the need to address the root causes of EVALI to prevent future outbreaks. An integrated approach from multiple perspectives is required, including public health; clinical, basic, and translational research; regulators; and users of e-cigarettes. Improving the public health response to reduce the risk of another substantial disease-inducing event depends on coordinated actions to better understand the inhalational toxicity of these products, informing the public of the risks, and developing and enforcing regulatory standards for all e-cigarettes.

1 February 2017 in Respiratory Medicine
Verified
Journal Article
Closed access
AMAnne C. Melzer
Anne C. Melzer
BGBijan J. Ghassemieh
Bijan J. Ghassemieh
SGSuzanne E. Gillespie
Suzanne E. Gillespie
PLPeter K. Lindenauer
Peter K. Lindenauer
MMMary Ann McBurnie
Mary Ann McBurnie
DADavid H. Au
David H. Au

19 November 2019 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
AMAnne C Melzer
Anne C Melzer
SGSara E. Golden
Sara E. Golden
SOSarah S. Ono
Sarah S. Ono
SDSantanu Datta
Santanu Datta
KCKristina Crothers
Kristina Crothers
CSChristopher G. Slatore
Christopher G. Slatore

1 October 2020 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
AMAnne C. Melzer
Anne C. Melzer
SGSara E. Golden
Sara E. Golden
SOSarah S. Ono
Sarah S. Ono
SDSantanu Datta
Santanu Datta
MTMatthew Triplette
Matthew Triplette
CSChristopher G. Slatore
Christopher G. Slatore
Rationale: Despite a known mortality benefit, lung cancer screening (LCS) implementation has been unexpectedly slow. New programs face barriers to implementation, which may include lack of clinician engagement or beliefs that the intervention is not beneficial. Objectives: To evaluate diverse clinician perspectives on their views of LCS and their experience with LCS implementation and processes. Methods: We performed a qualitative study of clinicians participating in LCS. Clinicians were drawn from three medical centers and represented diverse specialties and practice settings. All participants practiced at sites with formal LCS programs. We performed semistructured interviews with probes designed to elicit opinions of LCS, perceived evidence gaps, and recommendations for improvements. Transcribed interviews were iteratively reviewed and coded using directed content analysis. Results: Participants (N = 24) included LCS coordinators, pulmonologists, physician and nonphysician primary care providers (PCPs), a surgeon, and a radiologist. Most clinicians expressed their belief that the evidence supporting LCS was adequate to support clinical adoption, though most PCPs had little direct knowledge and based their decisions on local recommendations or endorsement by the U.S. Preventive Services Task Force. Many PCPs endorsed lack of knowledge of eligibility requirements and screening strategy (e.g., annual while eligible). Clinicians with more LCS knowledge, including several PCPs, identified a number of gaps in the current evidence that tempered enthusiasm, including unclear ideal screening interval, populations with high cancer risk that do not qualify under the U.S. Preventive Services Task Force guidelines, indications to stop screening, and the role of serious comorbidities. Support for centralized programs and LCS coordinators was strong but not uniform. Clinicians were frustrated by time limitations during a patient encounter, costs to the patient, and issues with insurance coverage. Many gaps in informatics support were identified. Clinicians recommended working to improve informatics support, continuing to clarify clinician responsibilities, and working on increasing public awareness of LCS. Conclusions: Despite working within programs that have adopted many recommended care processes to support LCS, clinicians identified a number of issues in providing high-quality LCS. Many of these issues are best addressed by improved support of LCS within the electronic health record and continued education of staff and patients.

11 May 2018 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
AMAnne C. Melzer
Anne C. Melzer
EPErika A. Pinsker
Erika A. Pinsker
BCBarbara Clothier
Barbara Clothier
SNSiamak Noorbaloochi
Siamak Noorbaloochi
DBDiana J. Burgess
Diana J. Burgess
SFSteven S. Fu
Steven S. Fu
Accurate smoking status is key for research purposes, but can be costly and difficult to measure. Within the Veteran’s Health Administration (VA), smoking status is recorded as part of routine care as “health factors” (HF)—fields that researchers can query through the electronic health record (EHR). Many researchers are interested in using these fields to track changes in smoking status over time, however the validity of this measure for assessing change is unknown. The primary goal of this project was to examine whether HFs can be used to accurately measure change in tobacco status over time, with secondary goals of assessing the optimum timeframe for assessment and variation in accuracy by site. Secondary analysis of the Veterans VICTORY study, a pragmatic smoking cessation randomized controlled trial conducted from 2009 to 2011. Eligible subjects were identified via the EHR using a past 90-day HF indicating current tobacco use (for example: “CURRENT SMOKER”, “CURRENTLY USES TOBACCO”). Participants were surveyed at 1 year to determine prolonged smoking abstinence. We identified HFs for tobacco status within +/− 120 days of the follow-up survey mailing date and recorded the temporally closest HF. Among subjects with both measures, we compared the two for agreement using kappa statistics and concordance. 1713 subjects (33%) had both follow-up survey and HF data, 1594 (31%) had only a survey response, 790 (15%) had only HF and 1026 (20%) had neither. For subjects with both measures, there was 90% concordance and moderate agreement (Kappa 0.48, 95%CI 0.41–0.55, Sensitivity 54.4, 95%CI 41.1–67.7, Specificity 94.3, 95%CI 87.5–100.0). We found high concordance but only moderate agreement by kappa statistics between HFs and survey data. The difference is likely accounted for by the natural history of quit attempts, in which patients cycle in and out of quit attempts. HFs appear to provide an accurate measure of population level quit behavior utilizing data collected in the course of clinical care.

1 February 2020 in Journal of the American College of Radiology
Verified
Journal Article
Closed access
AAAllison Aase
Allison Aase
AFAngela E. Fabbrini
Angela E. Fabbrini
KWKatie M. White
Katie M. White
SASarah Averill
Sarah Averill
AGAmy Gravely
Amy Gravely
AMAnne C. Melzer
Anne C. Melzer